Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that minoxidil increases cytosolic-free Ca2+ levels and induces cytotoxicity in PC3 human prostate cancer cells, with the cytotoxicity occurring in a Ca2+-independent manner.

This letter to the editor addresses corrections related to an earlier study on the effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer, but reports no new findings.

This study introduced a statistical method, PLACO, which revealed novel genetic regions associated with both Type 2 Diabetes and Prostate Cancer from GWAS data.

This randomized pilot study suggests that finasteride may benefit some men with category IIIA chronic pelvic pain syndrome, although it is not recommended as monotherapy unless benign prostatic hyperplasia is also present.

This review discusses the potential of plant polyphenols to overcome multidrug resistance in various solid cancers and reports no new experimental results; further research is suggested.

This study found that the Keyora Lycopene 23 in 1 formulation may improve various aspects of male endocrine and reproductive health by targeting oxidative stress, nitric oxide deficiency, and hormonal imbalance.

In this study, the researchers introduced the Keyora Lycopene 23 in 1 formulation, demonstrating its potential to improve male endocrine and reproductive health by addressing oxidative stress, nitric oxide deficiency, androgen imbalance, and mitochondrial dysfunction through a comprehensive multi-nutrient approach.

This study found that Dysphania ambrosioides oil exhibited cytotoxicity against U-937 lymphoma cells, indicating potential activity that warrants further investigation.

This study evaluates finasteride's safety and efficacy for treating male chronic pelvic pain syndrome, but the abstract does not report any results.

This paper discusses the role of steroid sulfatase in hormone-dependent tumors and highlights the development of potent inhibitors, noting the commencement of a phase I trial for one inhibitor in postmenopausal breast cancer patients.

This study found that testosterone therapy increased bone mineral density in older men with low testosterone, and combining it with finasteride may reduce prostate enlargement associated with testosterone treatment.

This review discusses the role of DHEA in intracrinology, highlighting its impact on breast and prostate cancer treatment and potential as a menopause therapy, but reports no new research findings.

Mutations in the androgen receptor gene cause androgen insensitivity, leading to female traits in genetically male individuals.

This document outlines recommendations from an international panel on testosterone therapy for aging men with late-onset hypogonadism, emphasizing the need for careful assessment and monitoring due to limited long-term safety data.

This review discusses the biochemical properties and clinical significance of 5 alpha-reductase isozymes and reports no new clinical results.

Male pattern baldness is largely genetic, linked to the androgen receptor gene, and may relate to certain health issues.

Male hormones affect COVID-19 severity and certain drugs targeting these hormones could help reduce the risk.

This article reviews considerations and guidelines for testosterone therapy in older men with low testosterone levels but does not provide new clinical results, emphasizing the need for ongoing evaluation and careful management, particularly regarding risks related to prostate and cardiovascular health.

This study found that oral finasteride 1 mg/day promotes hair growth and prevents further hair loss in a significant proportion of men with male pattern hair loss over two years.

This article discusses the structure of the human type II 5 alpha-reductase gene and reports no new experimental results.

This review discusses evidence on androgen sensitivity as a potential factor in COVID-19 disease severity, suggesting that androgen receptor interactions could influence virus entry and progression, and reports no new clinical results.

This study found that prenatal exposure to finasteride in rats led to permanent changes in developmental endpoints like anogenital distance and nipple retention, which were predictive of further reproductive tract malformations.

Dihydrotestosterone gel improved well-being and sexual function in older men without negatively affecting prostate health.

In this study, significantly fewer men treated with finasteride for moderate to severe BPH symptoms experienced acute urinary retention or required subsequent BPH-related surgery compared to placebo-treated patients.

This study concluded that daily treatment with 1 mg finasteride did not affect spermatogenesis or semen production in young men and had small, reversible effects on prostate volume and serum PSA.

This review discusses the role of 5α-reductase enzymes in androgen action and related disorders, noting that their specific inhibitory drugs show promise for conditions like benign prostatic hypertrophy; it reports no new clinical results.

This review discusses the pharmacological properties and clinical applications of cyproterone acetate and similar antiandrogens, noting previous failures in local applications due to concentration limitations; it reports no new empirical results.

This study indicated that while testosterone replacement in older men with low testosterone increases muscle mass and strength and reduces fat, its effects on physical function, disability, falls, or fractures remain unclear.

In this study, older men using 5α-reductase inhibitors for prostatic enlargement did not show increased risk of suicide, but had elevated risks of self-harm and depression.

Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.